Reactions 1680, p162 - 2 Dec 2017
Mild fatigue, easy bruising and atrial fibrillation:
2 case reports
In a case series, two patients were described, out of whom a
73-year-old woman developed mild fatigue and easy bruising
and a 77-year-old man developed atrial fibrillation during
treatment with ibrutinib [route, time to reactions onsets and
outcomes not stated].
Patient 1: A 73-year-old woman, who had a history of B-cell
prolymphocytic leukaemia, was started on ibrutinib 420mg
daily. She had also received rituximab and enoxaparin. Her
treatment course with ibrutinib was complicated by mild
fatigue and easy bruising. The treatment with ibrutinib was
maintained. She remained on ibrutinib for 15 months.
Patient 2: A 77-year-old man, who had a history of B-cell
prolymphocytic leukaemia, was started on ibrutinib
420 mg/day. His relevant medical history included coronary
artery disease and hypertension. He had also received
unspecified antibiotics and steroids, bendamustine and
rituximab. His treatment course with ibrutinib was
complicated by an episode of atrial fibrillation, which required
a brief discontinuation of ibrutinib therapy. Later, ibrutinib was
restarted and his constitutional symptoms resolved with
therapy. He remained on ibrutinib for 12 months.
Author comment: "Therapy was complicated by mild
fatigue and easy bruising, not requiring either dose
adjustment or interruption." "The treatment course was
complicated by an episode of atrial fibrillation which required
a brief interruption of ibrutinib therapy."
Gordon MJ, et al. Ibrutinib is an effective treatment for B-cell prolymphocytic
leukaemia. British Journal of Haematology 179: 501-503, No. 3, Nov 2017.
Available from: URL: http://doi.org/10.1111/bjh.14224 - USA
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved